Blanket Purchase Agreement 36F79723D003E-36E79723A0015
Award Date
6/2/23
Last Date to Order
5/3/24
Federal Agency
National Acquisition Center
Awardee
Bluebird Bio, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Federal Supply Schedule (FSS) contract, awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 12, allows the VA to procure drugs, pharmaceuticals, and hematology-related products from Bluebird Bio, Inc. through October 2028. The multiple-award, $300,000 contract under Schedule 65 IB enables the VA to acquire Bluebird Bio's gene therapies and hematology products to treat veterans with rare genetic disorders and blood diseases. Additionally, Bluebird Bio...
The Federal Supply Schedule (FSS) contract and Blanket Purchase Agreement (BPA) awarded to Bluebird Bio, Inc. by the U.S. Department of Veterans Affairs (VA) demonstrate the agency's interest in leveraging the company's gene therapies and hematology products to address the medical needs of the veteran population. The first IDV is a multiple-award, Schedule 65 IB FSS contract with a potential value of $300,000, which allows the VA's Veterans Integrated Service Network 12 to procure drugs,...
The National Acquisition Center, a civilian agency within the U.S. Department of Veterans Affairs (VA), awarded a single-award Blanket Purchase Agreement (BPA) to Krystal Biotech, Inc. to provide the company's VYJUVEK gene therapy treatment. The BPA has a ceiling value of $1,296,582.70 and a period of performance through August 2024. Krystal Biotech is a gene therapy biotechnology company focused on developing and delivering treatments for genetic, life-threatening, or rare diseases. In addition...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
The Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Viela Bio, Inc. for the delivery of Uplizna. With a potential value of $4,348,680, the BPA has a period of performance through December 28, 2020. Under this agreement, Viela Bio will provide the drug Uplizna to treat neuromyelitis optica spectrum disorder, a rare inflammatory disease of the central nervous system. The Department of Veterans Affairs procures pharmaceuticals...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 awarded a single-award Blanket Purchase Agreement (BPA) contract to Qiagen, LLC, a division of Qiagen N.V., to provide gene mutation analysis services focusing on the JAK2 gene. The total ceiling value of the BPA is $325,157.75 over a period of performance from March 2020 to March 2025. Under the BPA, the agency has awarded multiple fixed-price task orders to Qiagen, LLC to deliver genetic...
The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide the drugs TEGSEDI and ORFADIN. The BPA, valued up to $11.75 million, covers the period from October 2021 through September 2025. Sobi, Inc. also holds a multiple award schedule contract with the VA valued at up to $78 million through July 2025 for pharmaceutical products under the Federal...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Genentech USA, Inc. for the procurement of Evrysdi. The BPA has a potential value of $1 million and a period of performance from March 12, 2021 through September 14, 2023, with four one-year option periods. The BPA was established against the Pharmaceuticals and Drugs GSA Schedule and provides a contracting vehicle for ordering Evrysdi to treat spinal muscular atrophy. Spinal muscular...